AllSides Balanced Search reveals information and ideas from all sides of the political spectrum so you can get the full picture.
Dec 18 2020
The Food and Drug Administration authorized Moderna's Covid-19 vaccine for emergency use Friday, adding a second vaccine to the country's arsenal to fight the pandemic.
The United States is the first country to greenlight use of Moderna's vaccine, which was developed in part with the National Institutes of Health.
The news was met with optimism. "I've never been more hopeful thatNBC News (Online)
Dec 17 2020
The nation’s second coronavirus vaccine, produced by Moderna, could be on its way to thousands of sites nationwide by this weekend — a major accomplishment for a company that has never before brought a product to market.
An independent Food and Drug Administration advisory committee on Thursday endorsed the shot for adults 18 and over, and the agency is expected to issue an emergencyPolitico
Dec 07 2020
The two pharmaceutical companies closest to gaining U.S. clearance for a Covid-19 vaccine won’t attend a planned White House summit intended to build confidence in the shots.
Pfizer Inc. said in a statement that it had informed the White House that it wouldn’t attend the Tuesday event. Moderna Inc. executives also won’t be present, according to a person familiar with the matter.Newsmax (News)
Nov 19 2021
US regulators on Friday opened up Covid-19 booster shots to all US adults, expanding the government’s campaign to shore up protection and get ahead of rising coronavirus cases that may worsen with the holidays.
Pfizer and Moderna announced the Food and Drug Administration’s (FDA) decision after at least 10 states already had started offering boosters to all adults.
The latestThe Guardian
Nov 16 2020
Moderna’s coronavirus vaccine was nearly 95% effective and thwarted severe disease in an interim analysis, the company said Monday, putting a second drugmaker on track to request emergency approval before the end of the year.
The Cambridge, Massachusetts, company said it counted 95 cases within its trial of 30,000 participants. Only five of them were in the vaccine arm of the trial,Washington Times
Nov 12 2021
Europe’s drug regulator on Thursday confirmed it is investigating reports of a blood condition in recipients of Moderna’s mRNA COVID-19 vaccine.
According to a bulletin posted by the European Medicines Agency (EMA), it is reviewing six cases of capillary leak syndrome, considered a “very rare disorder,” after they were reported in the EMA’s EudraVigilance database.
“At this stageThe Epoch Times
Oct 20 2021
U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.
The Food and Drug Administration’s decisions mark a big step toward expanding the U.S. booster campaign, which began with extra doses of theAssociated Press
Apr 28 2022
Moderna asked Food and Drug Administration (FDA) regulators on Thursday to authorize its COVID-19 vaccine for emergency use in children under 6 years of age.
The biotech company said the shot was about 51% effective against the virus for kids under 2 years old and about 37% effective in kids ages 2 to 5.
It added that similar requests are underway with international regulatoryFox Business
Sep 19 2020
In recent days, the liberal media have dedicated a lot of effort into stoking fear the coronavirus vaccines being developed by multiple pharmaceutical companies under the Trump administration’s Operation Warp Speed, which put the full weight of the U.S. government behind developing and distributing a safe and effective vaccine. Of course, they were taking their cues from the Biden campaign andNewsBusters
Jul 27 2020
Moderna Inc. climbed as much as 11% Monday after getting a second round of U.S. funding for an experimental vaccine for COVID-19 and kicking off its late-stage trial.
With an additional $472 million award from the Biomedical Advanced Research and Development Authority (BARDA) announced on Sunday, Moderna’s shot is now backed by $955 million of funds from the U.S.
The firstNewsmax (News)